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1. Introduction
1.1. Nanoparticles: Physicochemical characteristics and applications in foods
Nanoparticles are elemental three dimensional structures that are typically between 1-100
nanometers (nm) in size that exhibit unique physiochemical characteristics that provide the
basis for their utilization, and present unique challenges associated with the development of
new applications [1, 2]. Because of their size, nanoparticles provide the opportunity to inter‐
act with human physiology at the subcellular level, affording many potential uses in nu‐
trient and drug delivery, vaccination therapies, and tissue repair. Specific physiologic
applications can be achieved by chemical modification of the nanoparticle to achieve in‐
creased blood circulation parameters thus increasing their residence time in the tissues, or
by the specific targeting of tissues using ligands. The uses of nanotechnology in foods are as
complex and varied as the types of formulations that can be created with this technology.
Current technological applications that impact foods include the manufacture of food pack‐
aging, including packaging that incorporates antimicrobial agents such as silver, [2] or de‐
tection particles (gold), flavor enhancement, and delivery of dietary supplements and
nutraceuticals [2-5]. While their potential or actual application present strong advantages, it
is imperative that there be a thorough understanding regarding the physiology of nanopar‐
ticle absorption, or the consequences of their containment or integration within the mamma‐
lian physiological and cellular environment.
1.2. Food packaging
Historically, food packaging has typically consisted of conventional materials such as paper
or metal-based materials. The use of polymeric formulations improved the ability to retain
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moisture and provided a gas barrier, thus extending food shelf life. Typically, the Food and
Drug Administration requires that the manufacturer of food contact material comply with
the regulatory requirements for each individual substance that comprises the entire formu‐
lation of the food contact material [6]. These food contact materials have typically included
paper, metallic-based items, and polymeric compounds such as polyethylene terephthalate
(PET), polypropylene, polyethylene, polystyrene, and others. Recently the formulation of
nanocomposites has improved the ability to produce food contact surfaces that are superior
with respect to their heating and gas barrier resistance characteristics [2, 7, 8]. Typically, a
combination of previously approved compounds and nano-material has been used for the
construction of the newer nanocomposite materials that strive to enhance the storage and
preservation of foods. Nanocomposites are described as a combination of inorganic nano‐
material and a continuous phase consisting of synthetic polymers [9]. Nanoclay composites
consist of magnesium aluminum silicate nanoparticles (bentonite or montmorillonite), and
have proven to be a superior gas barrier for the preservation of foods [7]. The production of
sustainable, biodegradable polylactide (PLA)-based polymers present the potential to re‐
duce the dependence upon petrochemical based polymers by using alternative renewable
sources to produce packaging materials with qualities comparable to presently used prod‐
ucts. The combination of PLA with montmorillonite (MMT) nanocomposite [10-12] has been
reported to produce a short term packaging material with good O2 gas permeability, and
can be converted into CO2 and H2O through decomposition by microorganisms [10].
Silver, which has long been recognized for its antimicrobial characteristics [13], has been
among the inorganic constituents incorporated into nanocomposite materials. Prior to the
advent of nanotechnology, silver had long been used as an ingredient within dental compo‐
site material [14], integrated into wound dressings [15-17] and other medical devices ap‐
proved by the FDA, and is recognized as a biocide by the EPA [18]. Analysis of the
antimicrobial effects of silver ion on gram positive and gram negative cell walled microor‐
ganisms demonstrated similar effects [19, 20]. Exposure of microbial organisms to silver re‐
sults in the retraction of the cytoplasm from the cell wall, condensation of the DNA into
electron-dense granules, and there is an accumulation of silver ions into the cytoplasm. The
damage, as inferred in these studies, is due to the inability to replicate at the DNA level [19].
Additional denaturant effects attributed to the silver ion include its ability to attach to sulf‐
hydryl groups, amino groups, and the terminal phosphate and carboxyl groups of bacterial
proteins [13], essentially inactivating the enzymes involved with electron transport and me‐
tabolism. Of the electron transfer functions, cytochrome reductase and cytochrome oxidase
are targeted [21]. While interest in silver’s use as an antimicrobial has increased due to the
observed rise in hospital and community-acquired antibiotic resistances, it is important to
note that a growing microbial resistance to silver has also been reported [22]. Antimicrobial
properties are similarly attributed to silver (Ag) nanoparticles [20, 23-27], and this property
has spurred the inclusion of this material into a wide array of products within the foods sec‐
tor including packaging and service containers, and bottles, or used as a measure to prevent
or control surface contamination by Escherichia coli and Staphylococcus aureus [28]. Indeed,
the incorporation of silver into MMT composite preparations was shown to inhibit the
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growth of Escherichia coli 0157:H7, Staphylococcus aureus, and Klebsiella pneumonia on agar at
levels that were 35% of the levels achieved by cefotaxime and chloramphenicol [29].
1.3. Dietary supplements and nutraceutical delivery
The encapsulation of dietary vitamins and other nutritional supplements as a nanoparticle
has  gained considerable  interest  as  a  means  to  increase  the  shelf  life  of  such materials,
and to  improve delivery and release  within the body.  The engineered particles  provide
potential  strategies  with which to overcome the impermeability of  the mucosal  epitheli‐
um, and offer a possible means of circumventing the degradation of the nutrient by harsh
degradative gastrointestinal conditions. Several candidate materials, used successfully for
the delivery of  drugs and vaccines,  have been examined for  their  ability  to encapsulate
nutrients.  Finally,  compounds  such  as  polysaccharides  and proteins  that  are  already  in
use within commercial  food applications  are  attractive  candidates  for  the  production of
new  nanocomposite  packaging  and  encapsulation  material,  as  several  are  generally  re‐
garded as safe and are biodegradable.
Poly (D,L)-lactic co glycolic acid (PLGA) nanoparticles are widely used for the encapsula‐
tion and delivery of drugs due to their reported biocompatibility and lack of overt toxicity.
The physicochemical properties of the PLGA particles are affected by specific formulation
and processing parameters, such as drug and polymer concentration, solvent volume, poly‐
mer molecular weight, the type of emulsifier used in the processing and its concentration,
and the aqueous-to-organic phase ratio [30, 31]. Thus, PLGA nanoparticles have been shown
to adequately encapsulate hydrophobic and hydrophilic molecules albeit the latter present
some challenges with respect to a lowered load efficiency, and many PLGA-encapsulated
delivery systems have been designed for a wide variety of macromolecules including drugs,
biologically active cytokines, and peptides [31-33].
Chitosan, an N-deacetylated derivative of chitin, has been analyzed for use in nutrient deliv‐
ery due to its wide acceptance in drug delivery, and is generally regarded as non-toxic and
biocompatible. Chitosan ((1฀ 4)-2-amino-2-deoxy-β-D-glucan) is a naturally occurring cati‐
onic polysaccharide found in the shells of shrimp, lobsters, and crab that has an intrinsic
ability to bind mucin. The bioadhesive property of chitosan permits organ-specific delivery,
and surface modification of the polysaccharide particle has been successfully used to alter
organ delivery [34]. Chitosan has been demonstrated to induce increased permeability in
Caco-2 monolayers across tight junctions as measured by changes in the measured transepi‐
thelial electrical resistance and in a 14C-mannose absorption assay [35, 36]. The improved ab‐
sorption across cell layers due to the opening of tight junctions is thought to be the result of
ionic interactions between the cell membrane and chitosan polysaccharide. While these
characteristics favor the polysaccharide’s use as a delivery method for a variety of com‐
pounds, it is necessary to incorporate anionic alginate to prevent burst release of the encap‐
sulated material due to protonation in an acidic environment. The results obtained by
encapsulation of Vitamin A within dual layered chitosan-alginate nanospheres have been
reported to be successful [37, 38]. In this instance, a high encapsulation efficiency and im‐
proved storage stability was achieved using double-layered microcapsules that incorporated
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chitosan, alginate, calcium chloride and Tween 20. The production of combined Chitosan/
PLGA spherical particles have also been reported for the encapsulation of Vitamin A
[38].With this construct, the microspheres (averaged 283 nm) demonstrated stability within
an acidic environment and a lowered release rate into the gastric environment when com‐
pared to particles composed solely of PLGA. Thus, release of the target nutrient would be
mainly in the small intestine where the vitamin would be absorbed. Interestingly, the mate‐
rial was visualized in the intestinal villi, and in the endothelium of rabbit GI.
Whey protein, derived from dairy, is recognized for its natural ability to form films and gels
[7]. Whey nanospheres containing alginate have demonstrated the controlled release of an en‐
capsulated nutrient, riboflavin, when tested in simulated gastric juices [39]. In this instance,
94 nm whey nanoparticles were constructed using an emulsification and cold gelation meth‐
od, which averts the use of toxic solvents, and modification of the alginate concentration pro‐
vides  some  control  over  degradation  of  the  particle  by  pepsin  in  their  assay.  The
encapsulation of viable probiotic yeast cells has been reported using whey –alginate micro‐
spheres produced by a cold gelation extrusion technique [40]. The encapsulation of a hydro‐
phobic,  fat-soluble  nutrient  can  be  achieved  using  casein  maltodextrin  nanoparticles
produced by the Maillard reaction. In this reaction, the ε-amine groups found on the protein’s
lysine residues are covalently bonded to the aldehyde of reducing sugars. Particles produced
in this manner consist of an exterior composed by the bulky hydrophilic domains of casein.
The result of this design is a particle with increased curvature, i.e., a smaller diameter, con‐
taining an outermost saccharide layer and a hydrophobic inner core. Once the optimal casein:
maltodextrin ratios were determined for the formation of the conjugates, incorporation of oil-
soluble vitamin D resulted in particles that were 30 nm in diameter and demonstrated signifi‐
cant protection of the vitamin at low pH values that simulated gastric juices [4].
Liposomes composed of polar lipids such as lecithin have been used as delivery systems for
antimicrobials, colors, and antioxidants. However, best results have been reported incorpo‐
rating an additional layer of material such as the cationic polysaccharide, chitosan. Lipo‐
somes  composed  of  soy  lecithin  and  prepared  by  homogenization,  and  combined  with
chitosan with stirring and sonication, were used to encapsulate grape seed extract [3]. In this
instance, the particle size increased with the addition of the grape seed extract due to surface
incorporation of the grape seed extract into the liposomes’ layer. This was rectified by produc‐
tion of particles containing multiple polymer layers composed of chitosan and citrus pectin;
grape seed polyphenols were no longer exposed to the matrix. Finally, microspheres with a
mineral composition have also been developed for the encapsulation of nutrients. In this case,
the encapsulation of water soluble polyphenols extracted from green tea has been accom‐
plished using calcium carbonate salt solutions containing phosphate and carbonate[41].
2. The Gut-Associated Lymphoid Tissue
The proposed and anticipated uses of orally-delivered nanoparticles, the use of nanoparti‐
cles on food-contact surfaces, and the introduction of microencapsulated nutrients, necessi‐
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tate an understanding of the events within the mucosal immune compartment known as the
Gut-Associated Lymphoid Tissue (GALT), which is critically involved in the formation and
maintenance of oral tolerance to introduced nutrient-derived antigens, and the generation of
mucosal immune responsiveness to ingested pathogens and their toxins. The gastrointesti‐
nal tract is responsible for the digestion and absorption of ingested nutrients. This function
is aided by the intestine’s mucosal lining, whose absorptive surface is greatly increased by
villi which project into the lumen and are composed of a single layer of epithelial cells and a
rich network of capillaries and lymphatics. While the gastrointestinal tract is responsible for
the absorption of nutrients, it is also the site of ongoing immune surveillance. The intestinal
lumen normally contains dietary degraded products, commensal microbial flora, and any
ingested contaminants including pathogenic bacteria and their products, viruses, fungi, or
parasites. The resident gastrointestinal immune system must: 1) generate immunologic tol‐
erance towards nutrients and the resident microflora, and 2) recognize and remove infec‐
tious agents and their toxins [42-44]. Oral tolerance is driven by prior administration of
antigen by the oral route, generating suppressive regulatory T cells, but is also dependent
upon the maintenance of an effective epithelial barrier. The role of the resident gastrointesti‐
nal CD4+ T cell population for the establishment and maintenance of the tolerant state is crit‐
ical [45, 46]. Investigators have reported the formation of exosome-like structures,
designated as "tolerosomes, " which are assembled in and released from small intestinal epi‐
thelial cells, that seem to play a crucial role for the induction of tolerance [47]. Breakdown of
oral tolerance is thought to lead to the development of food allergy and some autoimmune
diseases, including inflammatory bowel diseases (Crohn's disease and ulcerative colitis) and
celiac disease.
The GALT of the gastrointestinal tract consists of Peyer’s patches (PP) containing B cells,
dendritics, and T cells (Figure 1), appendix, draining mesenteric lymph nodes, and lymphat‐
ic follicles distributed throughout the length of the intestinal tract. The first line of immuno‐
logic defense is the provided by antibodies of the secretory IgA type found in the mucosal
secretions of the gut [48]. This is supported by the observation that individuals with IgA de‐
ficiencies demonstrate circulating immune complexes to bovine and milk proteins [49]. In
this case, the lack of IgA permits the entrance of food-derived antigens into the peripheral
circulation, resulting in immune complex formation. The production of IgA is now known
to be induced by regulatory T cells that have been activated by CD11+ dendritic cells [50].
Additionally, lymphocytes are scattered within the columnar epithelial layer (Intraepithelial
lymphocytes, or IEL) and throughout the lamina propria.
2.1. T cells of the Gut-associated lymphoid tissue
Beneath the epithelial layer of the mammalian gastrointestinal tract lies a rich source of im‐
munocompetent cells within the submucosal lymphoid follicles known as the intraepithelial
lymphocytes (IEL) that comprise a significant portion of the body’s T cells. The peripheral
immune system contains effector T lineage cells bearing the αβ Τ cell receptor (TCR) which
are either class II-restricted CD4+ T cells or class I-restricted CD8+T cells. Intraepithelial cells
are distinguished by the predominant presence of homodimeric CD8αα+ Τ cells and T line‐
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age cells containing the γδ TCR [51]; interestingly, the TCRγδ lineage and TCRαβ+CD8αα
populations do not retain immunologic memory of infection. However, the γδ-T cell en‐
riched IEL function as a surveillance system for damaged or infected epithelial cells, and
may modulate local immune responses by controlling cellular traffic and limiting mucosal
access of inflammatory cells [52]. The γδ Τ cells are thought to play an important role in the
pathophysiologic response to infections including Staphylococcal infection. In mice, 45% of
the IEL present in the small intestine are estimated to be conventional thymus-derived lym‐
phocytes that coexpress TCR-αβ and classical CD8-αβ. These cells primarily exhibit a cyto‐
lytic function and are recognized residents of the lamina propria, yet retain the ability to
dessiminate to various anatomical sites including the gut epithelium following an antigen
priming [53]. However, there are also TCR bearing αβ T cells in the lamina propria, the ma‐
jority of which exhibit the activated/memory phenotype; the major histocompatibility
(MHC) class II-restricted CD4+ T helper (Th) cells.
Figure 1. B220+ lymphocyte localization (indicated by arrows) in Peyer’s Patch derived from normal C57Bl/10J mice.
Formalin fixed tissue section [10X magnification) was stained using a monoclonal directed against B220 (RA3-6B2)
and a horse-radish peroxidase conjugated antibody. B220 staining demonstrates a predominance of B cells in the un‐
stimulated Peyer’s Patch.
2.2. T cell immune activity in the GALT
During a gastrointestinal immune response, ingested antigens in the lumen enter the Peyer’s
Patches via the specialized epithelial cells known as M cells present in the epithelial layer
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overlaying the PP. The M cells can take up particulate antigen by endocytosis and transport
the antigen into the interior of the PP where the dendritic cells process the antigen and
present antigen to the T cell areas of the PP and MLN, initiating T cell activation and differ‐
entiation into effector cells, that will either mediate tolerance or immunologic responsive‐
ness [54, 55]. In experiments using genetically-defined mice, ingestion of the superantigenic
food toxin, Staphylococcal entertoxin B (SEB), has been demonstrated to increase the TCR-
αβ populations in PP (Figure 2) such that the predominant response is generated as a result
of the binding between the toxin, target T cell receptor-bearing populations containing the
defined Vβ-8 sequence, and antigen presenting cells [56, 57].The result of this interaction is
the receptor-mediated induction of cytokine-driven T cell proliferation, resulting in a prolif‐
eration and expansion of the SEB-reactive Vβ-8+ T cells. As shown in Figure 2, normal PP
contain an abundance of B220+ B cells. However, the distribution of B220+ B cells becomes
dramatically altered following oral administration of SEB in quantities sufficient to induce
illness in humans to genetically-defined C57Bl/10J mice. The B220+ populations become se‐
questered, and the interior of the node becomes predominantly B220 negative. In this case,
the PP lymph node becomes enriched for Vβ-8+ T cells as determined by flow cytometric
analysis (Principato, unpublished). γδ-T lymphocyte populations in PP, lamina propria, and
epithelium have also been observed to increase following SE treatment [58].
Figure 2. A. Distribution of B220+ B cells in normal C57Bl/10J mice Peyer’s Patch. Formalin fixed tissue section was
stained using a monoclonal antibody directed against murine B220 (RA3-6B2) and a horse-radish peroxidase conju‐
gated antibody [10X magnification). B200 staining (brown areas) demonstrates a diffuse presence of B220+ B cells in
the unstimulated Peyer’s Patch. B. Expansion of non-B220+ (i.e., T cells) within Peyer’s Patches 6 days following inges‐
tion of Staphlyococcal enterotoxin B. A redistribution of the B220+ cells into aggregates forming below the PP epithe‐
lial capsule is indicated by arrows. [40X magnification).
2.3. T helper subsets of the GALT
The intestinal mucosa harbors all of the major T helper (Th) cell subsets (Th1, Th2, Treg (im‐
munoregulatory), Th17) that are defined by their lineage-specific transcription factor expres‐
sion, cytokine production, and immune function. The Th1 subset is critical for immune
responses generated against intracellular pathogens, and provides cytokine-mediated "help"
to the cytotoxic T lymphocytes. It is characterized by the production of interferon-gamma
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(IFN-γ) which is controlled by the transcription factor T-bet [59]. The Th2 subset provides
help for B cells and is also implicated in allergic sensitization, including those attributable to
foods [60]. The specific transcription factor for Th2 cells is GATA-3, which drives the synthe‐
sis of IL-4, IL-5, and IL-13 [61]. Tregs that have arisen from antigen-specific induction of
CD4+Foxp3+ T cells are critical for the induction of oral tolerance[62]. The Th17 cells express
retinoic acid-related orphan receptors (RORγt and RORα) that are needed for the transcrip‐
tion and synthesis of IL-17 [63, 64], and provide important protection of mucosal surfaces
against extracellular bacteria.
2.4. Innate immunity in the GALT
The cells of the innate immune system include macrophages, dendritic cells, and Langer‐
han’s cells, and are involved in critical activities pertaining to the initiation and support of T
cell-mediated, antigen-specific immunity. Significantly, the distribution of these cell types
includes the skin and epithelia that line the internal organs including the gastrointestinal
tract. Macrophages and dendritic cells are situated below the single layer of epithelial cells
that lines the Peyer’s Patches and lamina propria [65]. Macrophages have long been identi‐
fied as components of the reticuloendothelial system and are recognized for their ability to
ingest extracellular matter including proteins, cellular fragments, and debris that is foreign
to the body in the process known as phagocytosis. They are widely distributed within the
tissues of the body, and are crucial components of immune responsiveness and inflamma‐
tion. Initial binding of the target occurs on the surface of the cell, utilizing receptors with
specific capabilities. Receptors identified include surface Fc receptors that bind the Fc por‐
tion of IgG immunoglobulin, complement C3b and C3d receptors, MHC Class I and Class II,
Toll like receptors (TLR), cytokine receptors, and other membrane receptors such as the C-
type lectins [66] that provide additional innate functionality which supports the binding and
internalization of a wide variety of targets. Opsonization of target by plasma proteins is
known to improve phagocytosis, and the endocytosing vesicles have been demonstrated to
consist of clathrin structures [67, 68]. Interestingly, the endosome exhibits plasticity, and its
shape has been demonstrated to change depending on the material that is engulfed [69]. In
an early examination of macrophage activity, Unanue and coworkers demonstrated distinct
differences in macrophage effector function based on the anatomical source of the macro‐
phage. These investigators compared the ability of alveolar and peritoneal-derived macro‐
phages to bind and present antigen, the intracellular pathogen Listeria monocytogenes, to
previously sensitized T cells [70]. While alveolar and peritoneal macrophages both ex‐
pressed class II Ia antigen, alveolar macrophages were less efficient with respect to the up‐
take and presentation of antigen to sensitized T cells as compared to the peritoneal
macrophages. However, opsonizing Listeria using an anti-Listeria antiserum to coat the bac‐
terium enhanced the alveolar macrophages’ ability to engulf the bacterium and effectively
present the antigen to sensitized T cells. Once internalized, the ingested antigen undergoes
intracellular metabolic and proteolytic degradation, and modification. The resulting frag‐
ment [71, 72], is transported to the surface of the cell where it is presented in conjunction
with the major histocompatibility (MHC) gene molecule. This structural relationship is criti‐
cal for the activation of the appropriate responding T cell, which contains a great variability
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of gene sequences which must be rearranged to configure a mature, functional, TCR. This
permits the specific recognition of the presented peptide sequence by the TCR of the re‐
sponding T cell, and provides for the development of the adaptive immune response, which
will also generate an immunologic memory of the peptide target.
Innate immunity through the Toll like receptors (TLR) is conferred with the task of recogniz‐
ing a broad range of repetitive antigenic specificities that are found on a wide array of
pathogens. With this type of recognition, pathogen detection is based on the ability to recog‐
nize pathogen-associated molecular patterns using evolutionarily conserved, germline en‐
coded recognition receptors, the TLR [73-75]. Thus, while a strict sequence-dependent
antigenic specificity is not required as with antigen-specific immune responsiveness, what is
required is an ability to bind carbohydrate residues in a Ca++ dependent manner, and the
recognition of conserved molecular patterns such as in bacterial cell wall components. Thus,
LPS is the ligand for TLR 4, and targeted mutation of the TLR4 locus in mice results in LPS
non-responsiveness [76]. TLR2 recognizes ligands found on yeast cell walls, bacterial lipo‐
proteins [77], and lipoteichoic acid found in the cell walls of gram positive bacteria [78]; oth‐
er TLR recognize bacterial DNA, or double stranded viral RNA. In humans and mice, there
are now at least 10 such TLR identified. Unlike the sequence-specific receptors found on the
antigen-binding T cells of the adaptive immune response, TLR are non-clonal and do not re‐
quire gene rearrangement in order to become functionally mature.
Upon contact with a pathogen, the cells of the innate immune system become activated, the
binding of their receptors initiating signaling cascades that turn on required transcription of
target genes for the production of inflammatory cytokines, and the upregulation of costimu‐
latory and MHC molecules necessary for the direct elimination of the infection or for the re‐
cruitment of adaptive immune responses. The binding of TLR with their target ligand
induce costimulatory molecules that were first identified as the B7.1 and B7.2, or now refer‐
red to as CD80 and CD86. Thus, the responding T cell must recognize the modified target
ligand which is expressed on the surface of the macrophage or dendritic cells in the context
of both MHC and costimulator molecules with its sequence-specific TCR. It is clear that the
cells of the innate immune system are critical to the establishment of an effective immune
responsiveness against pathogens and for the recruitment of an efficient adaptive immune
response. The extremely successful yellow fever vaccine, YF-17D, which induces both
Th1/Th2 responses and generates powerful neutralizing antibodies in vaccine recipients,
was shown to induce such a strong protective immunity as a result of its ability to stimulate
multiple subsets of human dendritic cells and multiple TLRs [79]. Vaccine designs utilizing
synthetic 300 nm PLGA nanoparticles containing antigen and ligands that bind TLR 4 and
TLR 7 on the surface of dendritic cells, have successfully induced enhanced antigen-specific
antibody responses against the immunizing antigen when injected into experimental
mice[80]. The immunization protocol induced long-lived, high avidity antibody that was de‐
pendent upon the expression of the targeted TLR on both B cells and dendritics. The B cell
response indicated the generation of memory-type B cells.
Macrophage and dendritic cells have been documented with respect to the striking speciali‐
zations of the subsets. For instance, CD11b+ dendritic cells of the lamina propria can sample
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luminal microbes by extending their dendrites to interdigitate between neighboring intesti‐
nal epithelial cells [81], and have been reported to promote the differentiation of Th17+ regu‐
latory T cells following activation of TLR 5 due to exposure to bacterial flagellin [82].
Interestingly, as previously observed by Unanue and coworkers [70], anatomic localization
can denote distinctions in the functional effector function within subsets of cells. Thus,
CD11b+CD103+ dendritic cells of the lamina propia are found preferentially in the duode‐
num and rarely in the colon during the steady state, but accumulate in the lamina propria of
the colon along with Th17 cells during intestinal inflammation [83]. Macrophages of the
lamina propria have been demonstrated be hyporesponsive to certain inflammatory stimuli,
secrete IL-10, promote the differentiation of FoxP3+ regulatory T cells [84] and are able to
dampen some immune responses and intestinal inflammation. For instance, a severe dex‐
tran sulfate-associated experimental colitis can be induced in a macrophage-depleted trans‐
genic mouse or in clodronate-treated normal C57BL/6 or Babl/c mice [85]. Finally, CD103+
dendritic cells are known to assist in the antigen specific induction of FoxP3+ T regs necessa‐
ry for tolerance induction[86]. Thus, the cells of the innate immune system maintain a bal‐
ance between a normal state of tolerance, and inflammatory and autoimmune responses.
3. Ingestion of nanoparticles
The ingestion of nutrients with subsequent transit throughout the lumen of the gastrointesti‐
nal tract leads to the translocation of the material across the mucosa via the M cells of the
epithelial layer. M cells are specialized cells that exhibit endocytic activity, and are known to
transport antigens into the interior of the PP where the dendritic cells process the antigen
and present antigen to the T cell areas of the PP and MLN, initiating T cell activation and
differentiation into effector cells, that will either mediate tolerance or immunologic respon‐
siveness [54, 55]. Multiple physiochemical properties, including size and surface charge,
have been shown to influence nanoparticle uptake and absorption in the gut, and the extent
and rate at which the particles are removed from the circulation and their ultimate biodistri‐
bution. Thus, orally-administered non-ionic nanoparticles of 100 nm or less have demon‐
strated preferential absorption in the Peyer’s Patch and the small intestine. Focused,
engineered targeting of particles to the GALT has reported success with respect to the in‐
duction of measurable antibody responses. However, the specific immunologic mechanisms
inherent to nanoparticle intake and absorption within the gastrointestinal tract have not
been adequately identified, and the effector pathways that generate the immune responses
measured have not been characterized.
3.1. Influence of nanoparticle size and charge
Desai and coworkers demonstrated that 100 nm nanoparticles underwent a preferential up‐
take in the gastrointestinal tract [87] using an in situ rat ileal loop model. Polylactic polygly‐
colic acid (PLGA) nano- and microparticles were synthesized with averaged diameters of
100 nm, 500 nm, 1 µm, and 10 µm and infused into the tissue. Tissue uptake was quantified
as weight of the nanoparticles (µg) (taking into account the density of the polymer and the
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diameter of the microparticle) per square mm area of rat intestinal tissue. Infusion of the
particles into gastrointestinal tissue demonstrated 100 nm particle uptake by both duodenal
and ileal tissue. However, the ileum’s Peyer’s Patch and non-Peyer’s Patch tissue demon‐
strated a higher uptake of 100 nm size particles. This observation was repeated using surro‐
gate-loaded microparticles. Histologic examination of the tissue using fluorescent
microscopy confirmed a greater retention of the 100 nm nanoparticles, with a concentration
below the epithelial layer.
Figure 3. Schematic representation of the ingestion of nanoparticles. Macrophages and dendritic cells can be found
beneath the eptihelial layer of the GALT. Ingested nonionic or targetted nanoparticles distribute preferentially below
the intestinal epithelium, and can meet macrophages bearing class II and TLR molecules, and are phagocytosed by the
macrophage. Actively phagocytosing macrophages are represented in the foreground; engorged macrophages are
represented containing multiple particles.
The authors’ observations recollect those of an earlier study utilizing latex particles [88]. In
that study, Jani and coworkers conducted a 10-day feeding study in which non-ionic latex
particles ranging in size from 100 nm, 500 nm, 1 micron, and 3 microns were fed to Sprague-
Dawley rats. Their histologic and radiologic examination provided unequivocal evidence of
a preferential tissue distribution of 100nm particles in which the Peyer’s Patches, liver, and
spleen demonstrated significant uptake. Significantly, their result confirmed the potential
transport of particles from the gastrointestinal tract to the periphery via the lymphatics.
A separate 5 day feeding study in rats demonstrated the effects of a hydrophilic charge
upon the tissue distribution of normally hydrophobic polystyrene particles [89]. In this
study, commercial non-ionized polystyrene particles with a mean diameter of 60 nm were
compared to similarly-sized particles coated with poloxamer 407. Their results confirmed
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the earlier observations by Jani and coworkers: a preferential uptake of uncharged polystyr‐
ene was noted in the small intestines and Peyer’s Patches as measured using gel permeation
chromatography to quantify polystyrene in the tissue, and by microscopy. Further, a smaller
concentration of particles was observed to be in the mesenteric lymphatic tissue and liver.
Collectively, these data indicate a movement of the particles from the lumen of the intestinal
tract to the peripheral circulation with subsequent residence in other tissues. However,
charged particles demonstrated a significant reduction in uptake, 1.5%- 2% of the total ad‐
ministered dose of particles were absorbed as opposed to 10% uptake using uncharged par‐
ticles. Interestingly, the tissue distribution was altered as a result of the poloxamer coating:
the particles were particularly concentrated within the tissues of the large intestine. Taken
together, these results demonstrate the importance of particle size in determining the tissue
range of ingested neutrally charged particles, and the critical role of charge as a particularly
strong determinant of distribution within the body.
3.2. Biodistribution
The macrophage is most often implicated in the uptake of nanoparticles and opsonization
will influence nanoparticle uptake into the cells. Nevertheless, final biodistribution and dis‐
position is likely determined by the transport of particles by phagocytic and endocytotic
cells. The intraperitoneal injection of 40 nm gold nanoparticles in mice has been demonstrat‐
ed to result in the localization of particles in the Kupffer cells of the liver. In this research,
commercially-produced colloidal gold nanoparticles containing a negative surface charge, in
sizes of either 2 nm or 40 nm, were injected either intraperitoneally (ip) or intravenously (iv)
into C57Bl/6 mice, and detected within cryostat sections of liver and other organs by auto‐
metallography, which amplifies the detection of gold. Interestingly, a preferential uptake of
the 40 nm particles by Kupffer cells of the liver was observed 24 hours after ip injection.
Very little uptake was observed 1 hour after injection. Animals who received the particles by
ip injection also demonstrated particle uptake within the walls of the small intestine, mesen‐
teric lymph node, and in the spleen illustrating that transit of the administered particles had
occurred, most likely via the phagocytic cells [90]. Using a rabbit model, orally administered
chitosan/PLGA spherical particles (averaged 283 nm) for the encapsulation of Vitamin A
were found along the mucosal epithelium of the lumen, and within the intestinal epithelial
cells, presumably due to endocytosis. Macrophages in the lamina propia showed evidence
of particles as did the endothelial cells [38].
Variations to the particle, such as addition of a polymeric coating, will alter the biodistribu‐
tion. Thus, coating polystyrene 60 nm and 5.25 µm particles with poloxamer polymers will
decrease uptake by liver and spleen macrophages. Importantly, increasing the thickness of
the coating will alter uptake as well; in this case it has resulted in a reduction of uptake by
the peritoneal macrophage [91]. Experiments in which hydrophilic negatively-charged algi‐
nate-coated chitosan nanoparticles were passively absorbed into gastrointestinal tissue dem‐
onstrated localization beneath the follicle associated epithelium of the Peyer’s Patches and
agglomeration of the particles intracellularly, although the specific nature of the cell was not
described [92].
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Significant patterns in organ compartmentalization have also been described for metallic
nanoparticles.
The fate of ingested silver salt and silver nanoparticle was examined in a feeding study in
which separate groups of female Wistar rats were administered 9 mg silver acetate or 12.6
mg silver nanoparticle per kg of body weight daily for 28 days. It was estimated that 63% of
the daily ingested dose was excreted in the feces. The overall accumulation of either silver
ion or nanoparticle was similar, and appeared greatest in the small intestine while also de‐
tectable in liver, kidney, and stomach. Autometallographic staining (AMG) detects the pres‐
ence of either silver acetate or nanoparticle; thus, silver was localized to the lamina propia
and submucosa in the ileum. Interestingly, silver was concentrated around the veins and
portal circulation of the liver and was not preferentially taken up by the Kupffer cells of the
liver as was reported with injected gold [90]. Transmission electron microscopy displayed
similar localizations for both the silver nanoparticles and silver acetate; the material was
found within the lysosomes of the macrophages within the lamina propia of the ileum [93].
4. Immune responses and the ingested nanoparticle/microparticle
Particulate antigens are known to induce stronger immune responsiveness to the antigen
when compared to an immune response generated with the soluble form of antigen. Thus,
vaccine design has recently emphasized the use of nanoparticles to maximize induction of
the protective immune responsiveness. Mucosal immunizations have been viewed increas‐
ingly as an alternative to parenteral administration of vaccines, and features such as carbo‐
hydrate residue targeting by lectins has been examined by many groups [94-96].
Nevertheless, nanoparticle absorption within the GALT is still not well understood, and the
effector cellular interactions involved in the generation of the induced immune response
have not been fully defined.
Immunoglobulin production as a function of particle size, was measured by Gutierro and
coworkers [97]. Bovine Serum Albumin (BSA) –loaded PLGA microspheres of 200 nm, 500
nm, and 1000 nm were constructed using a double emulsion technique; size was determined
by laser diffractometry using a CoulterCounter® particle size analyzer. PLGA microspheres
containing BSA target antigen was administered by each of three routes: subcutaneously, in‐
tranasally, or orally into 6-8 week old Balbc/J mice and the elicited immune response was
measured by assaying IgG immunoglobulin production. Their results showed that IgG anti‐
bodies were elicited using each of the three sizes of microspheres when administered subcu‐
taneously; one size did not elicit greater antibody production than the others. Further, all
three sizes elicited antibody responses that were greater than that elicited using either solu‐
ble antigen or conventional adjuvant approaches. The oral immunization protocol consisted
of orally feeding each of the three sizes of microspheres, each containing 500 ∝g BSA, on
three successive days. Interestingly, oral administration of the loaded microspheres showed
that the 200 nm and 500 nm sized particles elicited fewer antibodies than an administration
of antigen with either alum or Freund’s adjuvant. The greatest production of serum IgG was
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demonstrated using the 1000 um size particle and this group contained the higher percent‐
age of individual responders. Analysis of serums at weeks 3 and 5 following immunization
did not reveal differences in IgG2a/IgG1 isotype profiles, the latter being indicative of
Th1/Th2 subset immunity and antigen-presenting differences. Ultimately, no differences
were found among the various sized particles, suggesting that the method of antigen pre‐
sentation was the same for all of the sizes tested. Again, the larger particles provided the
higher immunoglobulin production, regardless of the mode of immunization. These results
are interesting from the perspective of what has been reported [87, 88] regarding the effect
of size and nanoparticle biodistribution, and what is known about the distribution of effec‐
tor cells within the GALT. The present experiments used particles that were larger than
those previously published; it is likely that the biodistribution affected the manner in which
particulate antigen was presented for the induction of an immune response.
4.1. Targeting M cells in the GALT
Directed PLGA nanoparticles, using lectins to bind onto target sugar residues, has been shown
to be a means to achieve organ targeting for the induction of a systemic immune response. In
one study, PLGA nanoparticles were created by the double emulsion method and loaded with
hepatitis B surface antigen (HBsAg) [95]. Lectin directed to α-L- fucose residues, Tetragonolobus
purpureas, was bound to the nanoparticle using 1-ethyl-3-(3 dimethylaminopropyl) carbodii‐
mide to produce TLA lectin-PLGA-HBsAg nanoparticles that were measured to be 270 + 23nm
in size. Confocal microscopy confirmed binding of the particles to the M cells of the Peyer’s
Patches within immunized mice. Further, lectinized particles were stabilized by the addition of
hydrophilic trehalose, which improves the release of antigen. Therefore, nanoparticles stabi‐
lized with trehalose demonstrated an increased antigen release of 43.2+2.7% after 35 days, as
opposed to a release of 32.4 +2.3% by the non-stabilized equivalent. In this investigation, 10 mg
of encapsulated antigen per dose was used for the oral immunization of 8 week old Balb/c mice,
followed with a booster 2 weeks following the primary immunization. Thus, HBsAg -loaded
PLGA nanoparticles, TLA lectin-PLGA-HBsAg nanoparticles, trehalose-stabilized HBsAg -
loaded PLGA nanoparticles, and trehalose-stabilized TLA lectin-PLGA-HBsAg nanoparticles
were compared for the induction of antibody. Significantly, this study demonstrated the suc‐
cessful induction of antigen-specific IgG antibody by each of the engineered nanoparticles as
determined by ELISA assay of the immune seras, when compared to the levels of antibody pro‐
duced by the animals immunized with an alum based antigen. Isotyping of the antibodies
demonstrated induction of IgG1 antibody, indicative of a Th2 response, at levels that were
twice those attained by IgG2a which is indicative of a Th1 response. While demonstrable levels
of the Th1 cytokines, IL-2 and γ-IFN, were detected in the spleens of all nanoparticle-treated
animals, greater levels of γ-IFN were obtained with TLA lectin-PLGA-HBsAg, with or without
stabilization by trehalose. It is not known whether the engineered particle could have induced
a greater γ-IFN response as PLGA nanoparticles without antigen were not used for compari‐
son in this study.
A directed approach has been extremely successful using chitosan alginate microparticles [94].
In this instance, chitosan nanoparticles (CNP) prepared by the ionic gelation method were
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loaded with BSA test antigen, and coated with alginate. Thus, alginate was modified by using
1-ethyl-3-(3 dimethylaminopropyl) carbodiimide to form amide linkages between the carbox‐
ylate residues on alginate and the amino group of the lectin Ulex europaeus agglutinin (UEA-1).
The lectin Ulex europaeus agglutinin (UEA-1) was used to direct the microparticles towards the
α-L- fucose residues found on the surface of M cells. Confocal microscopy confirmed the tar‐
geting; punctate staining was visualized using the lectin-modified microspheres. The conjuga‐
tion and loading resulted in a particle shift in size: the particle size of the original CNP particle
is reported as 257+ 55.17 nm, while the lectin-modified antigen carrier CNP particle size in‐
creased to 1485 + 214.3 nm. Oral immunization of 6-8 week old Balb/c mice with each of the
preparations and control antigen provided striking differences in the antibody responses
against BSA antigen. The highest IgG titers were obtained using alum-absorbed BSA as the im‐
munogen’s positive control, and the lowest titers were obtained using BSA loaded CNP. In
contrast, antigen encapsulated in lectin-modified alginate chitosan particles (LACNP) consis‐
tently generated IgG titers that were greater than those obtained with CNP or ACNP formula‐
tions.  Demonstrable  levels  of  antigen-specific  IgG2a/IgG1  were  detected  with  all  three
formulations. Significantly, the highest titers of antigen-specific IgG were obtained with lectin-
modified microspheres, and the results seem to indicate that there was a greater IgG2a, or Th1
response, to antigen (BSA) with that particle. The original CNP particle and the alginate chito‐
san particles seemed to have induced a greater Th2 response.
Together, these studies demonstrate the induction of a Th1/Th2-induced immunity using en‐
gineered particles as do others [93]. However, it is not known whether α- fucose residues
are found on macrophages and dendritic cells present at other body sites, possibly resulting
in multiple pathways of immune responsiveness. As discussed earlier, Unanue and cowork‐
ers demonstrated distinct differences in macrophage effector function based on the anatomi‐
cal source of the macrophage [69]. Further, while TLA lectin-PLGA-HBsAg nanoparticles
induced the production of sIgA in saliva and gastrointestinal fluids, it was not reported
whether the engineered particles in these reports ultimately interacted with CD11+ dendritic
cells. IgA has been reported to be induced by regulatory T cells that have been activated by
CD11+ dendritic cells [50]. Finally, the directed attachment of the particles to the endocytotic
M cells of the epithelial layer presents the possibility that the particles were transcytosed by
the M cells towards CD103+ dendritic cells, found beneath the epithelial layer. In that case,
the possibility exists for the induction of tolerance [86]. Normal exposure to ingested, digest‐
ed antigen results in the production of regulatory T cells that suppress an immune response
in an antigen specific manner, resulting in tolerance and preventing food allergy. However,
the targeted microparticles document the induction of Th1and Th2 responses.
5. Future consideration: Ingested nanoparticle and immune allergic
dysfunction to foods
Proteins used in commercial food applications include casein, whey protein, collagen, egg
white, and fish myofibrillar protein, and popular plant-based proteins including soybean
protein and wheat gluten [7]. Compounds such as polysaccharides and proteins that are al‐
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ready in use within commercial food applications are attractive candidates for the produc‐
tion of new nanocomposite packaging and encapsulation material, as several are generally
regarded as safe and are biodegradable. However, food allergy has emerged as a growing
health problem throughout modern society, and current research efforts towards the identi‐
fication and characterization of clinically relevant food allergens are critical to our under‐
standing of their role in the immunopathogenic mechanisms involved in hypersensitivity
reactions, and the safety of novel and proposed food-oriented nanotechnology. Thus, the
characterization and identification of the proteins responsible for immune-mediated food al‐
lergies is critical.
In view of reported differences with respect to nanoparticle size and organ biodistribution,
it is interesting to note that particles are often detected below the epithelium of the gastroin‐
testinal tract. Since the Intraepithelial lymphocytes (IEL) reside below the epithelial layer of
the mammalian gastrointestinal tract, an understanding of the interactions between particle
and resident IEL is crucial. Following the ingestion of food, digested protein fragments, or
antigens, cross the epithelium to be processed and presented on the surface of class II mole‐
cule- bearing antigen presenting cells for recognition by specific TCR-bearing T cells. Aller‐
gic sensitization in the presence of IL-4 results in the generation of Th2 cells that will assist
the development of IgE+ B cells. A repeat encounter with the antigen will result in a food
allergic response. This event generates a skewed Th2 response, and will occur when luminal
antigen is introduced to IgE bound onto IgE Fc receptor on the surface of mast cells. Thus,
crossing the epithelial barrier to reach the mast cells is a critical step. The binding of antigen
to the receptor-bound complex will result in the release of histamine, serotonin and prosta‐
glandins in anaphylactic reactions including those generated by food.
Recent studies suggest that intestinal epithelial cells play a central regulatory role in deter‐
mining the rate and pattern of uptake of ingested antigens. This is particularly critical in
food allergy within the antigen-sensitized gastrointestinal tract. Studies using rats sensitized
to horseradish peroxidase (HRP) showed that intestinal antigen transport is keenly affected
by antigen-specific sensitization and is composed of 2 phases. The first phase consists of the
rapid transepithelial transport of specific antigen from the lumen, via endocytosis, into the
lamina propia. This phase is antigen specific, implying the existence of an antigen -specific
receptor on the surface of the epithelial cells, and occurs within 2 minutes in sensitized rats
as compared to a transit time of 20 minutes in non-sensitized, normal control animals. This
is followed by a flow of the antigen in tight junctions resulting in an increase of antigen
across the tissue. The second phase of antigen transport is not antigen specific, but is mark‐
edly increased by antigen challenge in sensitized rats compared with non-sensitized controls
[98], indicative of the paracellular penetration through the epithelium by antigen. These
studies clearly demonstrate that the kinetics of transport of antigen during IgE-mediated re‐
actions in the gastrointestinal tract is markedly increased across the epithelium. The result of
this transport is the generation of a Th2 response.
Finally, a feeding study using mice orally sensitized to the known milk allergens, casein, β-
lactalbumin, and β-lactoglobulin, provided compelling evidence regarding the importance
of the form of the antigen (soluble vs. particulate) for the induction of anaphylaxis [99]. The
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soluble proteins, β-lactalbumin, and β-lactoglobulin, resulted in anaphylactic reactions
when administered orally. Interestingly, the soluble proteins were detected in the lamina
propria of the small intestine of sensitized mice indicating that these proteins were able to
transcytose through the enterocytes in vivo. This observation was confirmed in vitro using
Caco-2 cells. Further, the challenge with sensitizing antigen resulted in significant levels of
serum IgG1, and low, but detectable levels, of serum IgE and IgG2a. Casein, normally
present within micelles, demonstrated a significant difference in anaphylactic induction. Or‐
al administration did not induce anaphylaxis. Instead, casein required a systemic adminis‐
tration (i.p. injection) in order to induce anaphylaxis; and it induced significantly higher
serum IgE and IgG1 (Th2) allergic responses as compared to the soluble milk allergens. Fur‐
ther, transcytosis by casein through Caco2 monolayers was poor compared to the soluble
milk allergens. When the tissue was examined by fluorescence microscopy, the casein was
detectable in the Peyer’s patches. Thus, these data indicated that the form of the sensitizing
antigen was critical to the induction of an anaphylactic response. Next, the soluble allergens,
β− lactoglobulin and soluble α-lactalbumin, were next converted into particulate aggregates
by pasteurization; the process reportedly abolishes the monomeric form and supports the
formation of aggregates of approximately 670 kDa. Pasteurization does not alter casein, and
it exists in two predominant types as it would in its natural state: 180 kDa and 670 kDa. The
conversion of soluble β− lactoglobulin and soluble α-lactalbumin into particulate aggregates
by pasteurization altered the immunogenicity of the proteins such that they now required a
systemic administration to induce anaphylaxis. Oral administration of either protein aggre‐
gate in sensitized mice did not induce anaphylaxis. The magnitude of the elicited serum
IgG1 and IgE immunoglobulin production was much greater than that induced by their
soluble forms. Further, the proteins were now detectable in association with the Peyer’s
Patches. Casein’s induction was not altered by the process. Taken together, these results
present the critical role of antigenic structure and its uptake across the epithelium as critical
factors contributing to the allergic state.
The allergic state presents serious challenges to the incorporation of nanoparticles in food
and food-associated products, particularly when considering the composition and ultimate
biodistribution of the particles. The engineering of nanoparticle containing materials impli‐
cated, related, or identified as allergens raises concern for the initiation of alternate allergy-
inducing pathways in the host. For instance, while casein is incorporated in a variety of
foods and is generally regarded as safe, it is also known to elicit strong allergic responses in
afflicted individuals with dairy intolerance. Disruption of the epithelial barrier is known to
result in gastrointestinal illness [100]. Infection and inflammation are conditions associated
with a disruption of the epithelial layer leading to the increased paracellular transport of lu‐
minal antigen. Cytokines such as IFN-γ and TNF-α directly affect barrier function of the epi‐
thelium, the latter being implicated in milk allergy [101-103]. Thus, the transit of
nanoparticle through a sensitized gastrointestinal system might result in a more complicat‐
ed scenario, depending upon the sensitizing antigen and the composition of the nanoparticle
itself. Thus, casein nanoparticle constructs, with or without targeting lectins, might not be
advisable for individuals with casein sensitivity. In this instance, the transit of the nanoparti‐
cle might be hastened across the layer, due to the pre-existing sensitivity, resulting in in‐
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creased transit through the layer, perhaps overwhelming the resident macrophage
phagocytic activity (Figure 4), leading to exacerbation of the allergic state or the generation
of alternative immunologic reactions.
Figure 4. Schematic representation of nanoparticle transit through the epithelial layer and the allergic state. An in‐
creased rate of transit by the nanoparticles is theorized as a result of the induction or presence of an allergic state.
6. Conclusions
The choice of material used in the formulation of nanoparticles and spheres during the for‐
mulation of encapsulated nutrients or supplements intended for ingestion can be critical to
the possible outcomes in mucosal immunity. A crucial consideration is whether the material
will influence the induction of either tolerance or active immunity to the introduced nutrient
as a result of its deposition within the gastrointestinal tract and possible interaction with res‐
ident effector cells.
The specific targeting of the nanoparticles and spheres using specific ligand interactions pro‐
vides an advantage in this respect. While polymers containing natural biodegradable mate‐
rials such as chitosan, PLGA, whey, casein, and others offer great advantages within this
technology, they also present further challenges towards an understanding of the mecha‐
nism involved in the maintenance of gastrointestinal immune homeostasis, and preventing
the induction or potentiation of immune dysfunction.
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